- cafead   Jun 30, 2022 at 11:22: AM
via “It's a wonderful morning for Lexicon, our scientists, clinicians and the patients and principal investigators,” summed up CEO and Director Lonnel Coats, as the biotech reported results from a phase 2 trial for its diabetic neuropathy therapy.
article source
article source